A recent study from Cancer Nursing has shed more light on the profound impact gynecologic cancer has on survivors, even after treatment. In particular, the study highlighted the prevalence of fear of recurrence among gynecologic cancer survivors, regardless of their prognosis, and underscores the importance of support programs to address survivors’ needs adequately. Through in-depth … Continued
Dr. Chi Lam Au Yeung of the University of Texas MD Anderson Cancer Center is a 2022 recipient of OCRA’s Early Career Investigator Grant. Her OCRA-funded project is focused on studying molecules produced by ovarian cancer cells in order to gain new insights into the interrelationship between different cell types in the progression of this … Continued
Snap summary: OCRA-funded researchers set out to improve immune response against a known therapeutic target, and provided a glimpse into a world where an ovarian cancer patient’s own immune system can be harnessed to treat and eradicate the disease. Researchers at Roswell Park Comprehensive Cancer Center have made significant gains toward immunotherapy as a viable … Continued
What to Know About the Chemotherapy Drug Shortage As many are aware, the U.S. is currently experiencing a matter of great concern: an ongoing shortage of chemotherapy drugs that are essential in the treatment of ovarian cancer. The availability of these medications is of critical importance to patients and their families, and we understand the anxiety … Continued
We know that germline genetic testing (testing that looks for inherited genetic mutations that exist in all cells of the body) is a crucial component in the fight against ovarian cancer — not just in determining who is at increased risk for the disease, but in optimizing treatment for patients already diagnosed. OCRA offers free … Continued
Written by Annie Ellis, OCRA Research Advocate and Scientific Advisory Committee member, and ovarian cancer survivor, based on expert presentations from the 2023 Annual Meeting of the Society of Gynecoologic Oncology. This year’s SGO annual meeting theme was Patients ● Purpose ● Progress. The meeting was held in Tampa, Florida from March 25th – 28th. … Continued
From March 25-28, 2023, gynecologic cancer experts from around the world converged on Tampa, Florida to participate in the Annual Meeting on Women’s Cancer hosted by the Society of Gynecologic Oncology. The meeting was packed with educational and scientific sessions highlighting the latest in the care of patients with gynecologic cancers. Below are some highlights of … Continued
A new study, published in the Journal of Clinical Investigation and funded in part by OCRA, has found that mesothelial cells are a critical factor in ovarian cancer metastasis. High-grade serous ovarian cancer, the most common ovarian cancer subtype, is known to be aggressive, and is associated with the presence of ascites and widespread metastases … Continued
We hope you’re feeling the love from the teal community this week, and always. We’re just seven weeks into 2023 and there’s so much to share — new grantees, a new website, and a bold, new direction in the fight against ovarian cancer. Research Advocacy Patient Support Ways to Give Did you know there are three simple ways … Continued
Ovarian cancer is not a single disease, but rather a group of diseases classified by type and subtype. And while they all affect the ovaries, they are quite unique in terms of origin and prognosis. High-grade serous ovarian cancer (HGSOC) is the most common subtype, accounting for the majority of diagnoses, and typically involving a first-line … Continued
OCRA is pleased to award $7 million in ovarian cancer research funding for 2023, representing the largest annual research investment in our history. With this funding, 20 cancer researchers at 15 medical institutions across the country will pursue projects that break new ground in the fight against this disease. Selected by OCRA’s Scientific Advisory Committee for their potential … Continued
An article published on February 2nd in The Washington Post highlights a turning point in our fight against ovarian cancer. As covered in the article, “Fallopian tube removal advised for more women to prevent ovarian cancer,” OCRA released a consensus statement, endorsed by the Society of Gynecologic Oncology, encouraging an aggressive prevention strategy: removal of the fallopian … Continued
Get email updates about research news, action alerts, and ways to join the fight.
